Beta-blockers may reduce all-cause mortality in HFpEF patients

Written By :  Aditi
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-19 06:00 GMT   |   Update On 2024-01-19 11:03 GMT
Advertisement

According to the American and European heart failure guidelines, HFpEF is defined as a condition with LVEF >=50% and accompanying signs and symptoms of heart failure, along with elevated left ventricular filling pressures, such as increased natriuretic peptide levels and hemodynamic measurements. It imposes a financial burden, affects healthcare system resource allocation, and is linked to higher morbidity and mortality rates.

Advertisement

According to a recently published meta-analysis, Current Problems in Cardiology, Beta-blockers can decrease all-cause mortality in individuals with heart failure with preserved ejection fraction (HFpEF). However, they did not affect cardiovascular mortality or rehospitalization.

Beta-blockers are commonly used to treat heart failure with reduced ejection fraction, but the same may not apply to HFpEF. This study aimed to evaluate beta-blockers impact on mortality and rehospitalization in HFpEF patients through a systematic review and meta-analysis. The primary outcomes were all-cause and cardiovascular mortality, all-cause and heart failure-related rehospitalization, and a composite of these endpoints.

Key Results from the study are:

  • Out of the 13,189 records, 16 full-text records met the inclusion criteria and analyzed.
  • 27,188 patients were recruited, with a mean age of 62 – 84 years old, predominantly female, with HFpEF.
  • 63.4% of patients received a beta-blocker, while 36.6% did not.
  • There was a significant reduction in all-cause mortality by 19% with an odds ratio of 0.81, whereas rehospitalization for heart failure (OR 1.13) or its composite with all-cause mortality (OR 1.01) was similar between the beta-blocker and control groups.

In conclusion, based on observational studies, beta-blockers can potentially reduce all-cause mortality in patients with HFpEF. Nevertheless, rehospitalization for heart failure or its composite with all-cause mortality.

Further investigations are warranted to clarify this uncertainty.

Reference:

Kaddoura, R., Madurasinghe, V., Chapra, A., Abushanab, D., Al‐Badriyeh, D., & Patel, A. (2024). Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis. Current Problems in Cardiology, 102376. https://doi.org/10.1016/j.cpcardiol.2024.102376


Tags:    
Article Source : Current Problems in Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News